Leveraging Proteomics for Target Identification & Mechanistic Insights in Pre-Clinical Drug Discovery

  • Use of limited proteolysis to identify candidate target proteins for Aquinnah Pharmaceuticals’ small molecule aimed at reducing tau pathology
  • Confirmation of target using siRNA screening using in-house phenotypic assays
  • Ongoing proteomic studies to define how the compound modulates target activity and its broader biological impact